• Cellectar Biosciences director Stefan D. Loren notified the board on May 17, 2026 that he will not stand for reelection as a Class III director at the 2026 annual meeting when his term expires.
• The decision was not tied to any disagreement over the company’s operations, policies, or practices.
• On May 18, 2026, the board appointed Andrew Gu as a Class III director.
• Gu is an analyst at Nantahala Capital Management, where he focuses on biotechnology investments.
• Gu was also named to the board’s audit committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-063202), on May 18, 2026, and is solely responsible for the information contained therein.